The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A Controlled Trial Comparing Continued Zidovudine with Didanosine in Human Immunodeficiency Virus Infection
Open accessAbstract
BACKGROUND: Although zidovudine is effective in patients with human immunodeficiency virus (HIV) infection, its efficacy may decline with prolonged use. Didanosine is another inhibitor of HIV reverse transcriptase. We evaluated the effectiveness of changing anti-HIV treatment from zidovudine to didanosine. METHODS: This multicenter, double-blind study involved 913 patients who had tolerated zidovudine for at least 16 weeks. The patients had the acquired immunodeficiency syndrome (AIDS), AIDS-related complex with less than or equal to 300 CD4 cells per cubic milliliter, or asymptomatic HIV infection with less than or equal to 200 CD4 cells per cubic milliliter. They were randomly assigned to receive 600 mg per day of zidovudine, 750 mg per day of didanosine, or 500 mg per day of didanosine. RESULTS: There were significantly fewer new AIDS-defining events and deaths among the 298 subjects assigned to 500 mg per day of didanosine than among the subjects who continued to receive zidovudine (relative risk, 1.39; 95 percent confidence interval, 1.06 to 1.82; P = 0.015). With 750 mg of didanosine, there was no clear benefit over zidovudine (relative risk, 1.10; 95 percent confidence interval, 0.86 to 1.42). The efficacy of didanosine was unrelated to the duration of previous zidovudine treatment. In the two didanosine groups, there were improvements in the number of CD4 cells (P less than 0.001 for both groups) and in p24 antigen levels (P = 0.03 in the 500-mg group; P = 0.005 in the 750-mg group), as compared with the zidovudine group. CONCLUSIONS: Changing treatment from zidovudine to 500 mg per day of didanosine appears to slow the progression of HIV disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Self-citationMitsuya, H., Weinhold, K. J., Furman, P. A., St Clair, M. H., Lehrman, S. N., Gallo, R. C., Bolognesi, D., Barry, D. W., & Broder, S. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.20.7096 · Cited by 1,866
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Larder, B. A., Darby, G., & Richman, D. D. (1989) · Science · doi:10.1126/science.2467383 · Cited by 1,559
Self-citationPrice, R. W., & Brew, B. J. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/158.5.1079 · Cited by 1,368
Volberding, P. A., Lagakos, S. W., Koch, M. A., Pettinelli, C., Myers, M. W., Booth, D. K., Balfour, H. H., Reichman, R. C., Bartlett, J. A., Hirsch, M. S., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004053221401 · Cited by 1,283
Self-citationThe Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Self-citation
Cited by
Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy
Hogg, R. S. (1998) · JAMA · doi:10.1001/jama.279.6.450 · Cited by 850
Pathogenesis of human immunodeficiency virus infection
Levy, J. A. (1993) · Microbiological Reviews · doi:10.1128/mr.57.1.183-289.1993 · Cited by 839
Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine
Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341602 · Cited by 745
Self-citationAntiretroviral Therapy for HIV Infection: A Knowledge-Based Approach to Drug Selection and Use
Moyle, G. J., Gazzard, B. G., Cooper, D. A., & Gatell, J. (1998) · Drugs · doi:10.2165/00003495-199855030-00005 · Cited by 536
Metadata
- Authors
- Kahn, J. O., Lagakos, S. W., Richman, D. D., Cross, A., Pettinelli, C., Liou, S.-H., Brown, M., Volberding, P. A., Crumpacker, C. S., Beall, G., Sacks, H. S., Merigan, T. C., Beltangady, M., Smaldone, L., & Dolin, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1992-08-27
- Volume
- 327
- Issue
- 9
- Pages
- 581-587
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2339921515
- Cited by
- 347
- References
- 35
- FWCI
- 42.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Controlled Trial Comparing Continued Zidovudine with Didanosine in Human Immunodeficiency Virus Infection. https://app.cochat.ai/papers/10.1056/nejm199208273270901
- The paper
- Kahn, J. O., Lagakos, S. W., Richman, D. D., Cross, A., Pettinelli, C., Liou, S.-H., Brown, M., Volberding, P. A., Crumpacker, C. S., Beall, G., Sacks, H. S., Merigan, T. C., Beltangady, M., Smaldone, L., & Dolin, R. (1992). A Controlled Trial Comparing Continued Zidovudine with Didanosine in Human Immunodeficiency Virus Infection. New England Journal of Medicine. https://doi.org/10.1056/nejm199208273270901
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.